Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.

[1]  J. Brady,et al.  Identification of Kaposin (Open Reading Frame K12) as a Human Herpesvirus 8 (Kaposi’s Sarcoma-Associated Herpesvirus) Transforming Gene , 1999, Journal of Virology.

[2]  A. Tulpule,et al.  Emerging treatments for epidemic (AIDS‐related) Kaposi's sarcoma , 1998, Current opinion in oncology.

[3]  M. Giacca,et al.  Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma. , 1998, European journal of cancer.

[4]  C. Boshoff,et al.  Kaposi's sarcoma herpesvirus as a new paradigm for virus‐induced oncogenesis , 1998, Current opinion in oncology.

[5]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[6]  J. Goedert,et al.  Spectrum of AIDS-associated malignant disorders , 1998, The Lancet.

[7]  J. Brady,et al.  Identification of Kaposin (Open Reading Frame K12) as a Human Herpesvirus 8 (Kaposi’s Sarcoma-Associated Herpesvirus) Transforming Gene , 1998, Journal of Virology.

[8]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[9]  D. Aboulafia.  Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. , 1998, Mayo Clinic proceedings.

[10]  R. Desrosiers,et al.  Deregulation of cell growth by the K1 gene of Karposi's sarcoma-associated herpesvirus , 1998, Nature Medicine.

[11]  R. Gallo.  Some aspects of the pathogenesis of HIV-1-associated Kaposi's sarcoma. , 1998, Journal of the National Cancer Institute. Monographs.

[12]  A. Albini,et al.  beta Interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid. , 1998, European journal of cancer.

[13]  T. Schulz,et al.  Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. , 1998, Journal of human virology.

[14]  E. Sandström,et al.  Induction of specific T‐cell responses in HIV infection , 1998, AIDS.

[15]  C. Pellet,et al.  Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. , 1997, AIDS.

[16]  S. Tyring,et al.  Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. , 1997, Journal of the American Academy of Dermatology.

[17]  A. Tulpule,et al.  Treatment of epidemic (AIDS-related) Kaposi's sarcoma. , 1997, Current opinion in oncology.

[18]  M. Testa,et al.  AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Conant,et al.  Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. , 1997, AIDS.

[20]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[21]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[22]  F. Neipel,et al.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? , 1997, Journal of virology.

[23]  C. Wood,et al.  Activation of HHV-8 by HIV-1 tat , 1997, The Lancet.

[24]  K. Petry.  HIV infection and neoplasia , 1996, The Lancet.

[25]  P. Simmonds,et al.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen , 1996, The Lancet.

[26]  Douglas D. Richman,et al.  Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .

[27]  W. Wilson,et al.  Treatment of HIV-associated Kaposi's sarcoma with paclitaxel , 1995, The Lancet.

[28]  M. Kaplan,et al.  Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma , 1995, The Lancet.

[29]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[30]  M. Feldstein,et al.  Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS‐related Kaposi's sarcoma , 1994, AIDS.

[31]  M. Raffeld,et al.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.

[32]  S. Monfardini,et al.  Treatment of acquired immunodeficiency syndrome (AIDS)-related cancer. , 1994, Cancer treatment reviews.

[33]  R. Mitsuyasu.  Clinical aspects of AIDS‐related Kaposi's sarcoma , 1993, Current opinion in oncology.

[34]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[35]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[37]  A. Swanson,et al.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. , 2001, The Mount Sinai journal of medicine, New York.

[38]  P. Diz Dios,et al.  Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. , 1998, Oral oncology.

[39]  M. Jacobson,et al.  Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. , 1998, AIDS.

[40]  R. Gallo,et al.  AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. , 1998, Journal of human virology.

[41]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .

[42]  A. Templeton,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome. , 1984, Medical and pediatric oncology.

[43]  O. L. Davies,et al.  Statistical Methods. 6th Edition. , 1968 .